Clovis Oncology Inc (CLVS.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|74||2009||Independent Chairman of the Board|
|54||2009||President, Chief Executive Officer, Director|
|54||2016||Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer|
|63||2009||Executive Vice President - Technical Operations, Chief Regulatory Officer|
|49||2015||Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer|
- BRIEF-Clovis Oncology Reports Q1 Loss Per Share $1.54
- BRIEF-Clovis Oncology CEO Patrick Mahaffy's 2017 Total Compensation Was $8.7 Million
- BRIEF-Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock
- BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $200 Mln Principal Amount Of Convertible Senior Notes
- BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $100 Mln Of Shares Of Co's Common Stock